Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Malignant neoplasm of colon and/or rectum
0.100 GeneticVariation disease BEFREE Current clinical guidelines recommend mutation analysis for select codons in KRAS and NRAS exons 2, 3, and 4 and BRAF V600E to guide therapy selection and prognostic stratification in advanced colorectal cancer. 31589789 2020
Malignant neoplasm of colon and/or rectum
0.100 Biomarker disease BEFREE We have used SW48 and LIM1215 human colon cancer cell lines, quadruple wild-type for KRAS, NRAS, BRAF and PI3KCA genes, and their HER2-amplified (LIM1215-HER2 and SW48-HER2) derived cells to perform in vitro and in vivo studies in order to identify novel therapeutic strategies in HER2 gene amplified human colorectal cancer. 31164152 2019
Malignant neoplasm of colon and/or rectum
0.100 GeneticVariation disease BEFREE Evaluation of the Idylla KRAS and NRAS mutation test in colorectal cancer tissue. 31207216 2019
Malignant neoplasm of colon and/or rectum
0.100 GeneticVariation disease BEFREE Clinical performance evaluation of the Idylla NRAS-BRAF mutation test on retrospectively collected formalin-fixed paraffin-embedded colorectal cancer tissue. 28899979 2018
Malignant neoplasm of colon and/or rectum
0.100 Biomarker disease BEFREE In colorectal cancer, KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4) mutations are associated with resistance to antiepidermal growth factor receptor monoclonal antibodies, and BRAF mutation is a molecular marker of poor prognosis. 29052598 2018
Malignant neoplasm of colon and/or rectum
0.100 GeneticVariation disease BEFREE The Japanese Society of Medical Oncology (JSMO) previously published 2 editions of the clinical guidelines: "Japanese guidelines for testing of KRAS gene mutation in colorectal cancer" in 2008 and "Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients" in 2014. 29873882 2018
Malignant neoplasm of colon and/or rectum
0.100 GeneticVariation disease BEFREE Common KRAS and NRAS gene mutations in sporadic colorectal cancer in Northeastern Iranian patients. 29921458 2018
Malignant neoplasm of colon and/or rectum
0.100 GeneticVariation disease BEFREE DNA methylation epigenotype and clinical features of NRAS-mutation(+) colorectal cancer. 28378457 2017
Malignant neoplasm of colon and/or rectum
0.100 GeneticVariation disease BEFREE EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells. 28560458 2017
Malignant neoplasm of colon and/or rectum
0.100 Biomarker disease BEFREE We selected one hundred and twenty eight patients diagnosed with advanced colorectal cancer with a KRAS and NRAS unmutated tumor. 26824184 2016
Malignant neoplasm of colon and/or rectum
0.100 GeneticVariation disease BEFREE Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients. 25800101 2015
Malignant neoplasm of colon and/or rectum
0.100 GeneticVariation disease BEFREE NRAS mutations occur in 3-5% of colorectal cancer. 24806288 2015
Malignant neoplasm of colon and/or rectum
0.100 Biomarker disease BEFREE The clinically relevant genetic aberrations described in this review include mutation analyses of RAS (KRAS and NRAS), BRAF and PI3K in colorectal cancer, KIT or PDGFR alpha as well as BRAF, NRAS and KIT in malignant melanoma. 26358176 2015
Malignant neoplasm of colon and/or rectum
0.100 Biomarker disease BEFREE Somatic mutations in KRAS, NRAS, and BRAF genes are related to resistance to anti-EGFR antibodies in colorectal cancer. 25954997 2015
Malignant neoplasm of colon and/or rectum
0.100 Biomarker disease BEFREE The added predictive value of additional biomarkers in the RAS-RAF-MAPK and PI3K-AKT-mTOR pathways in colorectal cancer is uncertain, which led us to systematically review the impact of alterations in KRAS (outside of exon 2), NRAS, BRAF, PIK3CA and PTEN in relation to the clinical benefit from anti-EGFR treatment. 24666267 2014
Malignant neoplasm of colon and/or rectum
0.100 GeneticVariation disease BEFREE The translational significance of this finding is highlighted by our observation that NRAS mutation correlates with a less favorable clinical outcome for patients with colorectal cancer. 23274911 2013
Malignant neoplasm of colon and/or rectum
0.100 GeneticVariation disease BEFREE Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation. 23400451 2013
Malignant neoplasm of colon and/or rectum
0.100 GeneticVariation disease BEFREE Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. 21305640 2011
Malignant neoplasm of colon and/or rectum
0.100 Biomarker disease BEFREE PIK3CA mutations were most frequent in squamous cervical (5/14, 36%), uterine (7/28, 25%), breast (6/29, 21%), and colorectal cancers (18/105, 17%); KRAS in pancreatic (5/9, 56%), colorectal (49/97, 51%), and uterine cancers (3/20, 15%); NRAS in melanoma (12/40, 30%), and uterine cancer (2/11, 18%); BRAF in melanoma (23/52, 44%), and colorectal cancer (5/88, 6%). 21829508 2011
Malignant neoplasm of colon and/or rectum
0.100 GeneticVariation disease BEFREE NRAS mutations are rare in colorectal cancer. 20736745 2010
Malignant neoplasm of colon and/or rectum
0.100 Biomarker disease BEFREE Herein, we demonstrate that the presence of an oncogenic KRAS allele results in elevated levels of GTP-bound N-RAS (N-RAS.GTP) in two human colorectal cancer cell lines, HCT 116 and DLD-1, compared to their isogenic counterparts in which the mutant KRAS allele has been disrupted by homologous recombination. 17130841 2007
Malignant neoplasm of colon and/or rectum
0.100 GeneticVariation disease BEFREE Four of the polymorphisms exhibited an increased colorectal cancer risk [GSTT1, NAT2 (phenotype), HRAS1, and ALDH2]. 12433710 2002
Malignant neoplasm of colon and/or rectum
0.100 GeneticVariation disease BEFREE We also carried out a meta-analysis of this study and 22 other published studies, estimating the relative risk of cancer (such as bladder, breast, or colorectal cancer) when one of the rare HRAS1 alleles was present. 8336750 1993